4-脒基苯基甲烷磺酰氯 | 71933-13-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-脒基苯基甲烷磺酰氯
• 英文名称: (p-amidinophenyl)methane sulfonyl fluoride
• 英文别名: p-APMSF；(4-Amidinophenyl)methanesulfonyl fluoride；(4-Carbamimidoylphenyl)methanesulfonyl fluoride
• CAS: 71933-13-6
• 化学式: C₈H₉FN₂O₂S
• mdl: MFCD00036898
• 分子量: 216.236
• InChiKey: PMHUSCHKTSTQEP-UHFFFAOYSA-N

物化性质

• 沸点：
  380.5±52.0 °C(Predicted)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  92.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (4-Carbamimidoylphenyl)methanesulfonyl chloride 生成 4-脒基苯基甲烷磺酰氯
  参考文献：
  名称：

  LAURA, R.;BING, D. H.

  摘要：

  DOI：

文献信息

• Amide compounds and use thereof
  申请人：——

  公开号：US20030158413A1

  公开（公告）日：2003-08-21

  The present invention relates to an amide compound of the formula 1 wherein R 1 is a hydrogen and the like, R 2 is a hydrogen and the like, X is SO 2 and the like, Y is the formula (III) and the like and a is 2, an isomer thereof or pharmaceutically acceptable salts thereof. The compound of the present invention shows a remarkable and selective Rho kinase inhibitory action, is free of problematic toxicity, shows fine oral absorption and drug kinetics (absorption, distribution, metabolism, excretion and the like of the drug), and shows superior properties (e.g., stability etc.) as a compound. Accordingly, it can be used as a therapeutic drug for various diseases in which Rho kinase is involved.

  本发明涉及一种式1的酰胺化合物，其中R1为氢等，R2为氢等，X为SO2等，Y为式（III）等，a为2，其异构体或其药学上可接受的盐。本发明的化合物显示出显著且选择性的Rho激酶抑制作用，不具有有毒性问题，显示出良好的口服吸收和药物动力学（药物的吸收、分布、代谢、排泄等），并且显示出优越的特性（例如稳定性等）作为一种化合物。因此，它可以作为治疗涉及Rho激酶的各种疾病的治疗药物。
• [EN] ASSAYS FOR LIGANDS FOR NUCLEAR RECEPTORS<br/>[FR] METHODES DE TITRAGE DE LIGANDS DE RECEPTEURS NUCLEAIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2000037077A1

  公开（公告）日：2000-06-29

  The present invention includes nuclear receptor heterodimer and nuclear receptor-coactivator peptide assays for identifying ligands for nuclear receptors, utilizing scintillation proximity and fluorescence resonance energy transfer (FRET), and methods of using identified ligands.

  本发明包括核受体异二聚体和核受体共激活剂肽的测定方法，用于识别核受体的配体，利用闪烁近距离和荧光共振能量转移（FRET），以及使用已确定的配体的方法。
• Pharmaceutical agent containing Rho kinase inhibitor
  申请人：——

  公开号：US20020032148A1

  公开（公告）日：2002-03-14

  A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of cerebrovascular contraction, a therapeutic agent of asthma, a therapeutic agent of peripheral circulation disorder, a prophylactic agent of immature birth, a therapeutic agent of arteriosclerosis, an anti-cancer drug, an anti-inflammatory agent, an immunosuppressant, a therapeutic agent of autoimmune disease, an anti-AIDS drug, a contraceptive, a prophylactic agent of digestive tract infection, a therapeutic agent of osteoporosis, a therapeutic agent of retinopathy and a brain function improving drug. In addition, the Rho kinase inhibitor is provided as a reagent and a diagnostic.

  提供了一种新型药物代理——Rho激酶抑制剂，特别用于治疗高血压、心绞痛、脑血管收缩抑制剂、哮喘、周围循环障碍的治疗剂、早产预防剂、动脉硬化的治疗剂、抗癌药物、抗炎剂、免疫抑制剂、自身免疫疾病的治疗剂、抗艾滋病药物、避孕药、消化道感染预防剂、骨质疏松症的治疗剂、视网膜病的治疗剂和脑功能改善药物。此外，Rho激酶抑制剂还可作为试剂和诊断工具。
• Vdac regulator
  申请人：Sugiyama Yasuo

  公开号：US20050234116A1

  公开（公告）日：2005-10-20

  The present invention provides a VDAC regulator comprising a compound represented by the formula (I): wherein R 1 is a halogen atom, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group or an optionally esterified or amidated carboxyl group; B is an optionally substituted aromatic group; X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom; and Y is a divalent hydrocarbon group or heterocyclic group, a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of Down's syndrome and the like, and the like.

  本发明提供了一种VDAC调节剂，其包含由式（I）表示的化合物：其中，R1是卤素原子、可选取代的杂环基、可选取代的羟基、可选取代的硫醇基或可选取代的氨基；A是可选取代的酰基、可选取代的杂环基、可选取代的羟基或可选酯化或酰胺化的羧基；B是可选取代的芳香基；X是氧原子、硫原子或可选取代的氮原子；Y是二价的烃基或杂环基、其盐或前药，该化合物有用作预防或治疗唐氏综合症等疾病的药物。
• Amidine derivatives for treating amyloidosis
  申请人：Chalifour J. Robert

  公开号：US20070021483A1

  公开（公告）日：2007-01-25

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

  本发明涉及在治疗与淀粉样相关疾病中使用氨基脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样相关疾病的方法，包括向受试者施用治疗剂量的氨基脲类化合物。根据本发明使用的化合物包括以下化学式的化合物，当施用时，可减少或抑制淀粉样纤维形成、神经退行性或细胞毒性：